News
LIXT
2.000
+4.71%
0.090
Weekly Report: what happened at LIXT last week (1202-1206)?
Weekly Report · 4d ago
Weekly Report: what happened at LIXT last week (1125-1129)?
Weekly Report · 12/02 11:44
Weekly Report: what happened at LIXT last week (1118-1122)?
Weekly Report · 11/25 11:35
Weekly Report: what happened at LIXT last week (1111-1115)?
Weekly Report · 11/18 11:31
Weekly Report: what happened at LIXT last week (1104-1108)?
Weekly Report · 11/11 11:47
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 11/05 12:05
Weekly Report: what happened at LIXT last week (1028-1101)?
Weekly Report · 11/04 11:44
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 10/29 16:30
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 10/29 12:08
Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Benzinga · 10/29 10:12
Weekly Report: what happened at LIXT last week (1021-1025)?
Weekly Report · 10/28 11:35
Lixte Biotechnology files to sell units, no amount given
Seeking Alpha · 10/23 11:23
Weekly Report: what happened at LIXT last week (1014-1018)?
Weekly Report · 10/21 11:30
Weekly Report: what happened at LIXT last week (1007-1011)?
Weekly Report · 10/14 12:03
Weekly Report: what happened at LIXT last week (0930-1004)?
Weekly Report · 10/07 11:51
Weekly Report: what happened at LIXT last week (0923-0927)?
Weekly Report · 09/30 11:43
Weekly Report: what happened at LIXT last week (0916-0920)?
Weekly Report · 09/23 11:41
Weekly Report: what happened at LIXT last week (0909-0913)?
Weekly Report · 09/16 11:30
Weekly Report: what happened at LIXT last week (0902-0906)?
Weekly Report · 09/09 11:43
Weekly Report: what happened at LIXT last week (0826-0830)?
Weekly Report · 09/02 11:46
More
Webull provides a variety of real-time LIXT stock news. You can receive the latest news about Lixte Biotechnology Hldgs Inc through multiple platforms. This information may help you make smarter investment decisions.
About LIXT
Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. The Company encompasses that inhibitors of protein phosphatases have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. It is focused on development activities of its LB-100 series of drugs. The LB-100 series have activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.